WASHINGTON DC (May 20, 2020) — The US Food and Drug Administration (FDA) has announced another step in their effort to harness diverse streams of data to understand and respond to COVID-19. The FDA has entered into an agreement with Aetion to collaborate on advanced analytical techniques to answer urgent coronavirus disease (COVID-19) research questions.